Visit
VJHemOnc is pleased to bring you a feature exploring the emerging applications of MRD in multiple myeloma.
VJHemOnc is pleased to bring you a feature exploring the latest thinking on the application of MRD in AML trials…
VJHemOnc is excited to bring you the latest research updates in lymphoid malignancies from the EHA 2022 Congress, which took…
For decades, autologous stem cell transplants (ASCTs) with high-dose chemotherapy has been the standard of care for patients with newly…
Axicabtagene ciloleucel (axi-cel) was approved by the FDA in October 2017 for patients with large B-cell lymphoma (LBCL) after two…
The U.S. Food and Drug Administration (FDA) has approved the use of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed chimeric antigen receptor…
On October 1, 2021, the US Food and Drug Administration (FDA) approved the use of brexucabtagene autoleucel, an autologous CD19-directed…
VJHemOnc is excited to bring you the latest updates from 18th International Myeloma Workshop (IMW) 2021, which brought together leading…
The introduction of chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) has significantly…
The 26th Congress of the European Hematology Association (EHA) 2021, which was held virtually from 9-17 of June, 2021, offered…
VJHemOnc is proud to present the NYC-Miami Myeloma MRD 2020 Virtual Meeting, which took place on the 8th of October…
The U.S. Food and Drug Administration (FDA) has approved the first and only assay – clonoSEQ®, to screen and assess…
In this session, Amer Zeidan, John Mascarenhas, Jan Bewersdorf & Rory Shallis discuss and debate the special considerations for managing…
Recently published in the Journal of Clinical Oncology, work from the Hourigan Lab (National Heart, Lung, and Blood Institute, National…
VJHemOnc is pleased to bring you e-learning webcasts from iwAL 2019. Catch up on key topics in acute leukemias now!
Explore the latest updates from Myeloma2018 with new e-learning webcasts available now!
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates
Keep up to date with all the latest news with our monthly newsletter